NewsBenzingaAcrivon Therapeutics avanza ACR-7280, mostrando regresión tumoral completa en modelos de LMA, con presentación de IND prevista para el primer semestre de 2027 Acrivon Therapeutics avanza ACR-7280, mostrando regresión tumoral completa en modelos de LMA, con presentación de IND prevista para el primer semestre de 2027 Benzinga 2026.10.20 12:36 (GMT+0) Open on Benzinga Other news Blockchain.com Launches Options Trading Feature Stocks Pressured by Tech Stock Weakness and Higher Crude Oil Prices Dear United Airlines Stock Fans, Mark Your Calendars for October 20 International Paper: A Potential DS Smith Sale Is Not Enough To Change Our Sell Rating Salesforce gets a chilly investor response to a $6 billion deal at a 58% premium 3M Company 2026 Q3 - Results - Earnings Call Presentation (NYSE:MMM) 2026-10-20
